bcda20190201_8k.htm

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

     
  FORM 8-K  
     

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d)

 

of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported):

 

January 28, 2019

     
     
  BioCardia, Inc.  
     
  (Exact name of registrant as specified in its charter)   
     

 

Delaware

0-21419

23-2753988

(State or Other Jurisdiction of

Incorporation or Organization)

(Commission File

Number)

(I.R.S. Employer

Identification Number)

 

125 Shoreway Road, Suite B

San Carlos, CA 94070

(Address of principal executive offices, including zip code)

 

(650) 226-0120

(Registrant’s telephone number, including area code)

 

Not Applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company     [ ] 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   [ ]

 

 

 
 

 

Item 7.01  Regulation FD Disclosure.

 

On January 28, 2019, BioCardia, Inc. (the “Company”) presented highlights of the business and its therapeutic candidates at the Forum for Innovative Regenerative Medicine in Tokyo, Japan.  A copy of the corporate presentation is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

 

The information furnished pursuant to this Item 7.01 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and shall not be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act except as shall be expressly set forth by specific reference in such filing.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit No.

  

Description

99.1

  

Corporate Presentation at the Forum for Innovative Regenerative Medicine, Tokyo, Japan

 

 
 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

Date: February 4, 2019

 

 

BIOCARDIA, INC.
   

 

By: /s/ Peter Altman
   
  Peter Altman
   
  Chief Executive Officer
   
  (Principal Executive Officer)